《上海证券报》、巨潮资讯网（www.cninfo.com.cn）刊载了《关于公司董事减持股份预披露公告》 （公告编号：2025035），公司董事王榕先生计划自减持公告披露之日起15个交易日后的3个月内（2025 年8月19日至2025年11月18日）以集中竞价方式减持不超过公司股份2,700,000股，占公司总股本（剔除 公司回购专用证券账户中股份数量）比例0.1369%。 近日，公司收到王榕先生出具的《关于股份减持计划期限届满暨实施结果的告知函》，截至本公告披露 日，王榕先生前次预披露的减持计划的期限已届满，现将其减持计划实施情况公告如下： 一、股东减持情况 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：002004 证券简称：华邦健康 公告编号：2025052 华邦生命健康股份有限公司 关于公司董事减持计划期限届满暨实施结果的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 华邦生命健康股份有限公司（以下简称"公司"）于2025年7月28日在《中国证券报》、《证券时报》、 二、其他相关说明 1、本次减持计划符合《证券法》《深圳证券交易所股 ...

证券代码：002004 证券简称：华邦健康 公告编号：2025052 华邦生命健康股份有限公司 关于公司董事减持计划期限届满暨实施结果的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 华邦生命健康股份有限公司（以下简称"公司"）于 2025 年 7 月 28 日在《中 国证券报》、《证券时报》、《上海证券报》、巨潮资讯网（www.cninfo.com.cn）刊 载了《关于公司董事减持股份预披露公告》（公告编号：2025035），公司董事王 榕先生计划自减持公告披露之日起 15 个交易日后的 3 个月内（2025 年 8 月 19 日至 2025 年 11 月 18 日）以集中竞价方式减持不超过公司股份 2,700,000 股，占 公司总股本（剔除公司回购专用证券账户中股份数量）比例 0.1369%。 近日，公司收到王榕先生出具的《关于股份减持计划期限届满暨实施结果的 告知函》，截至本公告披露日，王榕先生前次预披露的减持计划的期限已届满， 现将其减持计划实施情况公告如下： 一、股东减持情况 | 股东 名称 | 减持 方式 | | | 减持期间 | | | ...

证券日报网讯华邦健康（002004）11月17日在互动平台回答投资者提问时表示，公司发行的可交换债券 正处换股期，公司及控股子公司凯盛新材（301069）根据法规要求及换股进度及时履行信息披露义务， 具体情况请关注相关公告。 ...

（记者 王瀚黎） 每经AI快讯，有投资者在投资者互动平台提问：公司控股子公司凯盛新材可向下游供应电池级氯化亚 砜产品，请问年产能是多少？ 华邦健康（002004.SZ）11月17日在投资者互动平台表示，公司控股子公司凯盛新材生产的高纯度电池 级氯化亚砜已向相关生产企业供货，氯化亚砜产能等情况请关注凯盛新材披露的定期报告。 ...

格隆汇11月14日丨华邦健康(002004.SZ)在互动平台表示，河北生命原点是河北省干细胞库的建设和运 营方，其核心业务为新生儿干细胞、成人免疫细胞等细胞存储业务和干细胞产品临床研究和应用转化； 普瑞金主要从事细胞与基因治疗创新药物研发；谱新生物主要从事细胞与基因治疗药CDMO业务。 ...

Core Viewpoint - Huabang Health's stock price has shown significant growth this year, with a year-to-date increase of 21.27% and a recent surge in trading activity, indicating positive market sentiment towards the company [1][2]. Financial Performance - For the period from January to September 2025, Huabang Health achieved a revenue of 9.086 billion yuan, reflecting a year-on-year growth of 1.98%. The net profit attributable to shareholders was 612 million yuan, marking a substantial increase of 35.37% [2]. - The company has distributed a total of 4.909 billion yuan in dividends since its A-share listing, with 1.265 billion yuan distributed over the past three years [3]. Shareholder Structure - As of September 30, 2025, the number of shareholders for Huabang Health was 72,400, a decrease of 1.97% from the previous period. The average number of circulating shares per shareholder increased by 2.01% to 25,997 shares [2]. - The top ten circulating shareholders include Hong Kong Central Clearing Limited, which increased its holdings by 9.6272 million shares, and Southern CSI 1000 ETF, which entered the top ten with 14.4859 million shares [3]. Market Activity - On November 13, Huabang Health's stock rose by 2.14%, with a trading volume of 158 million yuan and a turnover rate of 1.62%. The total market capitalization reached 10.375 billion yuan [1]. - The stock has been active in the market, with a net inflow of 9.8835 million yuan from main funds and significant trading volumes in both buying and selling [1].

证券日报网讯 11月12日晚间，凯盛新材发布公告称，山东凯盛新材料股份有限公司（以下简称"凯盛新 材"）近日接到控股股东华邦生命健康股份有限公司（以下简称"华邦健康"）书面通知，获悉其非公开 发行的可交换公司债券触发提前赎回的条件，根据《华邦生命健康股份有限公司2025年面向专业投资者 非公开发行科技创新可交换公司债券募集说明书》有关条款约定，华邦健康决定行使发行人赎回选择 权。 （文章来源：证券日报） ...

Group 1 - The core viewpoint of the news is the initiation of large-scale clinical trials for gene-edited pig kidneys for human transplantation, marking a significant advancement in biotechnology and organ transplantation [1] - The first clinical trial was completed at NYU Langone Medical Center, approved by the FDA, aiming to evaluate the safety and efficacy of gene-edited pig kidneys for patients with end-stage kidney disease [1] - Global advancements in gene editing technology have been reported, including successful transplantation of gene-edited pig lungs in China and new treatment approaches for Down syndrome in Japan [1] Group 2 - Huazhong Securities highlights that breakthroughs in gene editing technology have significantly lowered the technical barriers for genetic modification, enabling large-scale industrial production of drugs [2] - In the A-share market, there are 22 listed companies with gene editing technology reserves, with mixed performance in stock prices; only 7 out of 22 companies saw gains on November 5 [4] - Among gene editing concept stocks, Shuanglu Pharmaceutical reported the highest net profit of 141 million yuan in the first three quarters, while Mengcao Ecological achieved a year-on-year profit increase of 48.73% [5][6] Group 3 - Eight gene editing concept stocks received attention from five or more institutions, with companies like Sturdy Medical and Huaxi Biological leading in institutional ratings [7] - Sturdy Medical announced a collaboration with Huazhong Agricultural University to establish a cotton research institute, focusing on gene editing and hybridization techniques for cotton seed improvement [7]

Group 1 - The company received notification from its controlling shareholder's concerted actor, Mr. Zhang Yizhuo, regarding the release of part of the shares pledged [1] - As of the announcement date, the cumulative pledge situation of shares held by Mr. Zhang Yizhuo and his concerted actors, including Chongqing Huibang Zhuoyuan Technology Co., Ltd., Mr. Zhang Songshan, and Ms. Zhao Danlin, is detailed [1] - The announcement includes a note that Mr. Zhang Songshan's held restricted shares are classified as executive locked shares [1] Group 2 - The company has prepared backup documents including the stock pledge repurchase agreement, account statements, and a detailed list of securities pledges and judicial freezes issued by China Securities Depository and Clearing Corporation Limited [2]

Core Viewpoint - Huabang Health is a leading enterprise in the field of clinical skin medications in China, with a comprehensive industrial chain advantage in the pharmaceutical and agricultural chemical sectors [1] Group 1: Business Overview - Huabang Health was established on March 11, 1992, and listed on the Shenzhen Stock Exchange on June 25, 2004, with its registered and office address in Chongqing [1] - The company's main business includes the research, production, and sales of pharmaceutical formulations, active pharmaceutical ingredients, and pesticides, as well as pharmaceutical distribution and import-export trade of pesticides [1] Group 2: Financial Performance - In Q3 2025, Huabang Health reported an operating revenue of 9.086 billion, ranking 9th among 110 companies in the industry, while the industry leader, East China Pharmaceutical, reported revenue of 32.664 billion [2] - The net profit for the same period was 879 million, placing the company 12th in the industry, with the top performer, Heng Rui Pharmaceutical, achieving a net profit of 5.76 billion [2] Group 3: Financial Ratios - As of Q3 2025, Huabang Health's debt-to-asset ratio was 44.95%, higher than the industry average of 35.26%, but down from 47.03% in the same period last year [3] - The company's gross profit margin was 37.01%, below the industry average of 57.17%, but slightly up from 36.81% year-on-year [3] Group 4: Executive Compensation - The chairman, Zhang Songshan, received a salary of 1.9466 million in 2024, an increase of 99,600 from 2023 [4] - The general manager, Zhang Haian, earned 1.8466 million in 2024, up by 144,000 from the previous year [4] Group 5: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 1.97% to 72,400, while the average number of shares held per shareholder increased by 2.01% to 26,000 [5] - Hong Kong Central Clearing Limited was the fifth-largest shareholder, increasing its holdings by 9.6272 million shares [5]